You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

CLINICAL TRIALS PROFILE FOR TIRZEPATIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for tirzepatide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03131687 ↗ A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus Completed Eli Lilly and Company Phase 2 2017-05-24 The purpose of this study is to evaluate the efficacy of the study drug tirzepatide in participants with type 2 diabetes mellitus.
NCT03311724 ↗ A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Completed Eli Lilly and Company Phase 2 2017-10-19 The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes.
NCT03322631 ↗ A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes Completed Eli Lilly and Company Phase 1 2017-11-15 The purposes of this study are to determine: - The safety of tirzepatide and any side effects that might be associated with it. - How much tirzepatide gets into the bloodstream and how long it takes the body to remove it. - How tirzepatide affects the levels of blood sugar. This study includes eight weekly doses of tirzepatide or placebo given as subcutaneous (SC) injections just under the skin. The study will last about 16 weeks (total), including screening and follow-up. This study is for research purposes only and is not intended to treat any medical conditions.
NCT03375463 ↗ A Study of Tirzepatide (LY3298176) in Healthy Participants Completed Eli Lilly and Company Phase 1 2017-12-19 This study has three parts. Each participant will enroll in one part. Part A: The purpose of Part A is to compare study drug tirzepatide solution formulation to a powder formulation mixed with water and given subcutaneously (SC) (just under the skin). Part A will measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Part B: The purpose of Part B is to evaluate the safety and tolerability of tirzepatide intravenous (IV) formulation when administered into a vein. Part C: The purpose of Part C is to evaluate the safety and tolerability of tirzepatide following multiple SC weekly doses of a solution. This study will last approximately 70 days for Part A or Part B and 92 days for Part C. This does not include screening. Screening is required within 28 days prior to the start of the study.
NCT03482024 ↗ A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function Completed Eli Lilly and Company Phase 1 2018-03-30 The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for tirzepatide

Condition Name

Condition Name for tirzepatide
Intervention Trials
Obesity 22
Type 2 Diabetes 15
Overweight 13
Type 2 Diabetes Mellitus 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for tirzepatide
Intervention Trials
Diabetes Mellitus, Type 2 30
Diabetes Mellitus 29
Obesity 18
Overweight 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for tirzepatide

Trials by Country

Trials by Country for tirzepatide
Location Trials
United States 490
China 138
Mexico 86
Brazil 73
Germany 68
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for tirzepatide
Location Trials
Florida 29
California 27
Texas 26
Georgia 19
Missouri 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for tirzepatide

Clinical Trial Phase

Clinical Trial Phase for tirzepatide
Clinical Trial Phase Trials
Phase 4 6
Phase 3 26
Phase 2 9
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for tirzepatide
Clinical Trial Phase Trials
Completed 21
Not yet recruiting 20
Recruiting 12
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for tirzepatide

Sponsor Name

Sponsor Name for tirzepatide
Sponsor Trials
Eli Lilly and Company 53
Dr Adnan Agha 1
University Health Network, Toronto 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for tirzepatide
Sponsor Trials
Industry 54
Other 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.